How do you approach patient selection for starting intravitreal complement inhibitors?

Because complement inhibition seems to have only a modest effect on GA progression, no clear functional benefit in pivotal trials, and a not-insignificant risk of CNV and optic neuropathy, I tend toward a conservative view when deciding whether to recommend it to patients.

A good candidate, in my v...